Evidence map›Paper›PMID 29874139›Full record

ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018

Surveillance for Late Effects in Childhood Cancer Survivors.

Wendy Landier, Roderick Skinner, W Hamish Wallace, Lars Hjorth, Renée L Mulder, F Lennie Wong, Yutaka Yasui, Nickhill Bhakta, Louis S Constine, Smita Bhatia and 2 more

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 3 pooled it
18.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 3 syntheses or guidelines pooled it, 196 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. A portable survivorship care plan: a tool that helps educate and improve knowledge in childhood cancer survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Prevalence of childhood cancer in Canada: an analysis using 5-year, 18-year and 25-year limited-duration prevalence from the CYP-C data tool.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025
    Article
  18. Article
  19. Article
  20. Article

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Wendy LandierWendy Landier and Smita Bhatia, University of Alabama at Birmingham, Birmingham, AL; Roderick Skinner, University of Newcastle upon Tyne, Newcastle upon Tyne; W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom; Lars Hjorth, Skåne University Hospital, Lund, Sweden; Renée L. Mulder and Leontien C. Kremer, Emma Children's Hospital, Amsterdam; Leontien C. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; F. Lennie Wong, City of Hope, Duarte, CA; Yutaka Yasui, Nickhill Bhakta, and Melissa M. Hudson, St Jude Children's Research Hospital, Memphis, TN; and Louis S. Constine, University of Rochester Medical Center, Rochester, NY.
Roderick SkinnerWendy Landier and Smita Bhatia, University of Alabama at Birmingham, Birmingham, AL; Roderick Skinner, University of Newcastle upon Tyne, Newcastle upon Tyne; W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom; Lars Hjorth, Skåne University Hospital, Lund, Sweden; Renée L. Mulder and Leontien C. Kremer, Emma Children's Hospital, Amsterdam; Leontien C. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; F. Lennie Wong, City of Hope, Duarte, CA; Yutaka Yasui, Nickhill Bhakta, and Melissa M. Hudson, St Jude Children's Research Hospital, Memphis, TN; and Louis S. Constine, University of Rochester Medical Center, Rochester, NY.
W Hamish WallaceWendy Landier and Smita Bhatia, University of Alabama at Birmingham, Birmingham, AL; Roderick Skinner, University of Newcastle upon Tyne, Newcastle upon Tyne; W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom; Lars Hjorth, Skåne University Hospital, Lund, Sweden; Renée L. Mulder and Leontien C. Kremer, Emma Children's Hospital, Amsterdam; Leontien C. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; F. Lennie Wong, City of Hope, Duarte, CA; Yutaka Yasui, Nickhill Bhakta, and Melissa M. Hudson, St Jude Children's Research Hospital, Memphis, TN; and Louis S. Constine, University of Rochester Medical Center, Rochester, NY.
Lars HjorthWendy Landier and Smita Bhatia, University of Alabama at Birmingham, Birmingham, AL; Roderick Skinner, University of Newcastle upon Tyne, Newcastle upon Tyne; W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom; Lars Hjorth, Skåne University Hospital, Lund, Sweden; Renée L. Mulder and Leontien C. Kremer, Emma Children's Hospital, Amsterdam; Leontien C. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; F. Lennie Wong, City of Hope, Duarte, CA; Yutaka Yasui, Nickhill Bhakta, and Melissa M. Hudson, St Jude Children's Research Hospital, Memphis, TN; and Louis S. Constine, University of Rochester Medical Center, Rochester, NY.
Renée L MulderWendy Landier and Smita Bhatia, University of Alabama at Birmingham, Birmingham, AL; Roderick Skinner, University of Newcastle upon Tyne, Newcastle upon Tyne; W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom; Lars Hjorth, Skåne University Hospital, Lund, Sweden; Renée L. Mulder and Leontien C. Kremer, Emma Children's Hospital, Amsterdam; Leontien C. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; F. Lennie Wong, City of Hope, Duarte, CA; Yutaka Yasui, Nickhill Bhakta, and Melissa M. Hudson, St Jude Children's Research Hospital, Memphis, TN; and Louis S. Constine, University of Rochester Medical Center, Rochester, NY.
F Lennie WongWendy Landier and Smita Bhatia, University of Alabama at Birmingham, Birmingham, AL; Roderick Skinner, University of Newcastle upon Tyne, Newcastle upon Tyne; W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom; Lars Hjorth, Skåne University Hospital, Lund, Sweden; Renée L. Mulder and Leontien C. Kremer, Emma Children's Hospital, Amsterdam; Leontien C. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; F. Lennie Wong, City of Hope, Duarte, CA; Yutaka Yasui, Nickhill Bhakta, and Melissa M. Hudson, St Jude Children's Research Hospital, Memphis, TN; and Louis S. Constine, University of Rochester Medical Center, Rochester, NY.
Yutaka YasuiWendy Landier and Smita Bhatia, University of Alabama at Birmingham, Birmingham, AL; Roderick Skinner, University of Newcastle upon Tyne, Newcastle upon Tyne; W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom; Lars Hjorth, Skåne University Hospital, Lund, Sweden; Renée L. Mulder and Leontien C. Kremer, Emma Children's Hospital, Amsterdam; Leontien C. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; F. Lennie Wong, City of Hope, Duarte, CA; Yutaka Yasui, Nickhill Bhakta, and Melissa M. Hudson, St Jude Children's Research Hospital, Memphis, TN; and Louis S. Constine, University of Rochester Medical Center, Rochester, NY.
Nickhill BhaktaWendy Landier and Smita Bhatia, University of Alabama at Birmingham, Birmingham, AL; Roderick Skinner, University of Newcastle upon Tyne, Newcastle upon Tyne; W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom; Lars Hjorth, Skåne University Hospital, Lund, Sweden; Renée L. Mulder and Leontien C. Kremer, Emma Children's Hospital, Amsterdam; Leontien C. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; F. Lennie Wong, City of Hope, Duarte, CA; Yutaka Yasui, Nickhill Bhakta, and Melissa M. Hudson, St Jude Children's Research Hospital, Memphis, TN; and Louis S. Constine, University of Rochester Medical Center, Rochester, NY.
Louis S ConstineWendy Landier and Smita Bhatia, University of Alabama at Birmingham, Birmingham, AL; Roderick Skinner, University of Newcastle upon Tyne, Newcastle upon Tyne; W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom; Lars Hjorth, Skåne University Hospital, Lund, Sweden; Renée L. Mulder and Leontien C. Kremer, Emma Children's Hospital, Amsterdam; Leontien C. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; F. Lennie Wong, City of Hope, Duarte, CA; Yutaka Yasui, Nickhill Bhakta, and Melissa M. Hudson, St Jude Children's Research Hospital, Memphis, TN; and Louis S. Constine, University of Rochester Medical Center, Rochester, NY.
Smita BhatiaWendy Landier and Smita Bhatia, University of Alabama at Birmingham, Birmingham, AL; Roderick Skinner, University of Newcastle upon Tyne, Newcastle upon Tyne; W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom; Lars Hjorth, Skåne University Hospital, Lund, Sweden; Renée L. Mulder and Leontien C. Kremer, Emma Children's Hospital, Amsterdam; Leontien C. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; F. Lennie Wong, City of Hope, Duarte, CA; Yutaka Yasui, Nickhill Bhakta, and Melissa M. Hudson, St Jude Children's Research Hospital, Memphis, TN; and Louis S. Constine, University of Rochester Medical Center, Rochester, NY.
Leontien C KremerWendy Landier and Smita Bhatia, University of Alabama at Birmingham, Birmingham, AL; Roderick Skinner, University of Newcastle upon Tyne, Newcastle upon Tyne; W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom; Lars Hjorth, Skåne University Hospital, Lund, Sweden; Renée L. Mulder and Leontien C. Kremer, Emma Children's Hospital, Amsterdam; Leontien C. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; F. Lennie Wong, City of Hope, Duarte, CA; Yutaka Yasui, Nickhill Bhakta, and Melissa M. Hudson, St Jude Children's Research Hospital, Memphis, TN; and Louis S. Constine, University of Rochester Medical Center, Rochester, NY.
Melissa M HudsonWendy Landier and Smita Bhatia, University of Alabama at Birmingham, Birmingham, AL; Roderick Skinner, University of Newcastle upon Tyne, Newcastle upon Tyne; W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom; Lars Hjorth, Skåne University Hospital, Lund, Sweden; Renée L. Mulder and Leontien C. Kremer, Emma Children's Hospital, Amsterdam; Leontien C. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; F. Lennie Wong, City of Hope, Duarte, CA; Yutaka Yasui, Nickhill Bhakta, and Melissa M. Hudson, St Jude Children's Research Hospital, Memphis, TN; and Louis S. Constine, University of Rochester Medical Center, Rochester, NY.
Great North Children's Hospital · GB

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
Towards a preventive cancer vaccine for children with constitutional mismatch repair deficiencyUG1CA189955 · NCI · PUBLIC HEALTH INSTITUTE · PI BRAD H POLLOCK, Michael E. Roth · 2014 to 2026
$62.5M
The St. Jude Lifetime CohortU01CA195547 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HUDSON, MELISSA M, NESS, KIRSTEN KIMBERLIE · 2015 to 2024
$14.9M
NCI NIH HHS P30 CA021765NCI NIH HHS U01 CA195547NCI NIH HHS UG1 CA189955
6 · The paper itself

Abstract

Many childhood cancer survivors carry a significant risk for late morbidity and mortality, a consequence of the numerous therapeutic exposures that contribute to their cure. Focused surveillance for late therapy-related complications provides opportunities for early detection and implementation of health-preserving interventions. The substantial body of research that links therapeutic exposures used during treatment of childhood cancer to adverse outcomes among survivors enables the characterization of groups at the highest risk for developing complications related to specific therapies; however, methods available to optimize screening strategies to detect these therapy-related complications are limited. Moreover, the feasibility of conducting clinical trials to test screening recommendations for childhood cancer survivors is limited by requirements for large sample sizes, lengthy study periods, prohibitive costs, and ethical concerns. In addition, the harms of screening should be considered, including overdiagnosis and psychological distress. Experts in several countries have developed guideline recommendations for late effects surveillance and have collaborated to harmonize these recommendations internationally to enhance long-term follow-up care and quality of life for childhood cancer survivors. Methods used in these international efforts include systematic literature searches, development of evidence-based summaries, rigorous evaluation of the evidence, and formulation of consensus-based surveillance recommendations for each late complication. Alternate methods to refine recommendations, such as cumulative burden assessment and risk prediction and cost-effectiveness modeling, may provide novel approaches to guide survivorship care in this vulnerable population and, thus, represents a worthy objective for future international survivorship collaborations.

Indexed as

Cancer SurvivorsChildHumansMass ScreeningMorbidityNeoplasmsPractice Guidelines as TopicQuality of Life

Identifiers

PMID29874139
PMCPMC6804892
OpenAlexW2806287189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.